ReproCell Stock

ReproCell Depreciation & Amortization

The Depreciation & Amortization of ReproCell (4978.T) as of Sep 10, 2026 is 18.45 M JPY. In the previous year, Depreciation & Amortization was 16.25 M JPY — a change of 13.54% (higher).

Depreciation & Amortization

18.45 MJPY

YoY

13.54%

Last updated:

Depreciation & Amortization of ReproCell is 2026 18.45 M JPY. Depreciation & Amortization of ReproCell was 2025 16.25 M JPY. It decreases by 13.54% higher compared to the previous year.

The ReproCell Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2018
234.52 M JPY
Jan 1, 2019
34.59 M JPY
Jan 1, 2020
41.44 M JPY
Jan 1, 2021
26.60 M JPY
Jan 1, 2022
18.02 M JPY
Jan 1, 2023
13.55 M JPY
Jan 1, 2024
16.25 M JPY
Jan 1, 2025
18.45 M JPY
The ReproCell Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
18.45 MJPY+13.54%
16.25 MJPY+19.91%
13.55 MJPY-24.80%
18.02 MJPY-32.26%
26.60 MJPY-35.80%
41.44 MJPY+19.81%
34.59 MJPY-85.25%
234.52 MJPY+0.41%
233.56 MJPY-19.51%
290.17 MJPY
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Depreciation & Amortization of ReproCell is 18.45 M JPY in 2026.

Depreciation & Amortization of ReproCell changed from 16.25 M JPY to 18.45 M JPY, representing a 13.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization ReproCell since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's ReproCell historically and in real time.

Access this data via the Eulerpool API

Income Statement — ReproCell

All Key Metrics — ReproCell